MAXONA Pharmaceuticals Initiates Phase 2 Trials for Non-Opioid Pain Relief

MAXONA Pharmaceuticals Initiates Phase 2 Clinical Trial for MAX-001



MAXONA Pharmaceuticals, based in Malvern, Pennsylvania, has recently embarked on an important milestone in pain management by dosing the first participant in its Phase 2 clinical trial of MAX-001. Designed to tackle acute pain, particularly after surgical extraction of impacted third molars, MAX-001 stands out as a promising non-opioid and non-NSAID oral therapy. This trial, registered as NCT07937657, aims to evaluate both the safety and efficacy of this innovative treatment.

The Rationale Behind MAX-001



MAX-001 is an optimized extended-release formulation of nefopam, which has been widely prescribed outside of the United States for managing moderate to severe acute and chronic pain. Nefopam operates as a triple neurotransmitter re-uptake inhibitor, enhancing pain relief by primarily affecting norepinephrine levels and also engaging serotonin and dopamine pathways. This unique mechanism positions it as a potentially effective alternative in the quest to minimize opioid reliance, which has become a pressing public health issue.

Shawn Fatholahi, President and CEO of MAXONA Pharmaceuticals, emphasized the urgent need for alternatives to opioid-based pain management. Both the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have called attention to the necessity for expanding non-opioid pharmacologic treatments. Fatholahi noted, "The launch of this Phase 2 clinical trial marks a significant moment for our Company, and our goal is to offer healthcare professionals innovative, safe, and effective options for pain relief."

Clinical Trial Details



The Phase 2 trial is a randomized, double-blind, placebo-controlled study targeting the efficacy of MAX-001 over a range of doses. A total of 276 patients undergoing the extraction of bilateral impacted third molar teeth will participate in this study, which is overseen by Dr. Todd Bertoch, Chief Medical Officer of CenExel Medical Research. Dr. Bertoch is recognized for his expertise in pain therapeutics and has been instrumental in clinical trials supporting analgesic drug development.

According to Dr. Bertoch, the Dental Impaction Pain Model (DIPM) employed in this trial is acknowledged as the gold standard for acute pain research, allowing researchers to precisely assess how efficiently an experimental painkiller alleviates surgical discomfort. This model's capabilities greatly enhance the trial’s ability to produce valid and actionable data.

Prior Successes and Future Prospects



MAXONA Pharmaceuticals previously reported successful outcomes in Phase 1 trials, where MAX-001 showed good tolerability without serious adverse events or troubling lab results. This foundation gives confidence for the continuation of clinical studies, as the drug holds promise for a safe pain management alternative.

If all goes well, and if MAX-001 receives authorization from the FDA, it could revolutionize non-opioid pain therapy in the United States, becoming the only approved triple monoamine re-uptake inhibitor indicated for the treatment of acute pain.

As the pharmaceutical industry continues to wrestle with the implications of opioid use, the development of medications like MAX-001 becomes increasingly vital. MAXONA’s commitment to innovate in pain relief therapies underscores the industry’s shift towards seeking safer options for patients and healthcare providers alike.

More information on MAXONA’s advancements and ongoing research can be found at MAXONA Pharmaceuticals.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.